Alfred E. Tiefenbacher GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alfred E. Tiefenbacher GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10543
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alfred E. Tiefenbacher GmbH & Co KG (AET) is an independent pharmaceutical company that focuses on the development of active pharmaceuticals ingredients. It offers products in the forms of tablets, capsules, oral solution, patches, long acting injectables, ophthalmic solution and inhaled therapies. The company develops and supply finished dosage form (FDF) generic pharmaceuticals to marketing organizations internationally. AET also provides services such as active pharmaceutical ingredient (API) sourcing; clinical trials; quality assurance; registration; supply chain; marketing and sales; and intellectual property services. The company operates in India, Cyprus, Malta, China and the US. AET is headquartered in Hamburg, Germany.

Alfred E. Tiefenbacher GmbH & Co KG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Alfred E. Tiefenbacher Receives Technology of Pramipexole from Hyundai Pharmaceutical 10
Alfred E. Tiefenbacher Forms Joint Venture with Combino Pharm 11
AET BioTechnologie Enters Into Co-Development Agreement With BioXpress Therapeutics For Adalimumab Biosimilar 12
Licensing Agreements 13
Hyundai Pharm Enters Into Licensing Agreement With Alfred E. Tiefenbacher For Pramipexole SR 13
Alfred E. Tiefenbacher GmbH & Co KG – Key Competitors 14
Alfred E. Tiefenbacher GmbH & Co KG – Key Employees 15
Alfred E. Tiefenbacher GmbH & Co KG – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Joint Venture 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfred E. Tiefenbacher GmbH & Co KG, Deals By Therapy Area, 2012 to YTD 2018 8
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Alfred E. Tiefenbacher Receives Technology of Pramipexole from Hyundai Pharmaceutical 10
Alfred E. Tiefenbacher Forms Joint Venture with Combino Pharm 11
AET BioTechnologie Enters Into Co-Development Agreement With BioXpress Therapeutics For Adalimumab Biosimilar 12
Hyundai Pharm Enters Into Licensing Agreement With Alfred E. Tiefenbacher For Pramipexole SR 13
Alfred E. Tiefenbacher GmbH & Co KG, Key Competitors 14
Alfred E. Tiefenbacher GmbH & Co KG, Key Employees 15
Alfred E. Tiefenbacher GmbH & Co KG, Other Locations 16
Alfred E. Tiefenbacher GmbH & Co KG, Subsidiaries 16
Alfred E. Tiefenbacher GmbH & Co KG, Joint Venture 16

List of Figures
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Alfred E. Tiefenbacher GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GNI Group Ltd (2160):製薬・医療:M&Aディール及び事業提携情報
    Summary GNI Group Ltd (GNI) is a healthcare service provider that researches, develops, manufactures and markets pharmaceutical drugs. The company’s business operations consist of drug discovery activities such as drug discovery research, drug discovery infrastructure, fundamental drug discovery, an …
  • Safe Orthopaedics SA (SAFOR):企業の製品パイプライン分析2018
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws, per …
  • Xeltis AG:企業の製品パイプライン分析2018
    Summary Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process refe …
  • Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical dev …
  • Abano Healthcare Group Ltd (ABA)-製薬・医療分野:企業M&A・提携分析
    Summary Abano Healthcare Group Ltd (Abano Healthcare), formerly ElderCare New Zealand Ltd is a healthcare service provider that offers Dental, Audiology, Radiology and medical services. The company also operates business in community pathology and radiology sector. It operates businesses in sectors …
  • Kala Pharmaceuticals Inc (KALA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company that offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III …
  • Lloyds Banking Group Plc:戦略・SWOT・企業財務分析
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • International Speedway Corporation:企業の戦略・SWOT・財務情報
    International Speedway Corporation - Strategy, SWOT and Corporate Finance Report Summary International Speedway Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Pharmascience Inc-製薬・医療分野:企業M&A・提携分析
    Summary Pharmascience Inc (Pharmascience) is a pharmaceutical company that develops, manufactures and markets medicinal products. The company offers generic, prescription, over-the-counter and private label OTC products. It offers drugs in therapeutic areas of anti-inflammatory, cancer, cardiovascul …
  • Foley Family Wines Limited:企業の戦略・SWOT・財務情報
    Foley Family Wines Limited - Strategy, SWOT and Corporate Finance Report Summary Foley Family Wines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Stock Spirits Group PLC:企業の戦略・SWOT・財務分析
    Stock Spirits Group PLC - Strategy, SWOT and Corporate Finance Report Summary Stock Spirits Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Orbis S.A.:戦略・SWOT・企業財務分析
    Orbis S.A. - Strategy, SWOT and Corporate Finance Report Summary Orbis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Marubeni Corporation:企業の戦略・SWOT・財務情報
    Marubeni Corporation - Strategy, SWOT and Corporate Finance Report Summary Marubeni Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Enmax Corp:企業の戦略的SWOT分析
    Enmax Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Deyaar Development:企業の戦略・SWOT・財務情報
    Deyaar Development - Strategy, SWOT and Corporate Finance Report Summary Deyaar Development - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • LMI Aerospace, Inc.:企業の戦略的SWOT分析
    LMI Aerospace, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • EnCana Corporation (ECA):石油・ガス:M&Aディール及び事業提携情報
    Summary EnCana Corp (EnCana) is an oil and gas producer. The company explores, develops, produces and markets natural gas, oil and natural gas liquids (NGLs). Its major resource plays include Montney, Duvernay, Wheatland Oil play, Deep Panuke, Horn River and other emerging plays in Canada. In the US …
  • Control4 Corp (CTRL):企業の財務・戦略的SWOT分析
    Control4 Corp (CTRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • American Eagle Outfitters Inc:戦略・SWOT・企業財務分析
    American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report Summary American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Standard Motor Products Inc:企業の戦略・SWOT・財務情報
    Standard Motor Products Inc - Strategy, SWOT and Corporate Finance Report Summary Standard Motor Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆